Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2016;133:e38-e360
   PubMed Web of Science ®Google Scholar
• Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591-608
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke 2013;44:2361-75
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl 2):S1-S45
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 2015;9:129-69
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012;223:251-61
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016;68:92-125
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. Clinical guideline [CG181]. July 2014. www.nice.org.uk/guidance/cg181. Accessed December 12, 2016
   Google Scholar
• Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007;115:2398-409
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. Am J Cardiovasc Drugs 2008;8:419-27
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed March 28, 2017
   Google Scholar
• Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004;22(Suppl3):49-61
   PubMed Web of Science ®Google Scholar
• Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 2016;316:743-53
   PubMed Web of Science ®Google Scholar
• Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151:786.e1-10
   Web of Science ®Google Scholar
• Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7
   PubMed Web of Science ®Google Scholar
• Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013;44:691-8
   PubMed Web of Science ®Google Scholar
• Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2014. Natl Vital Stat Rep 2016;65:1-122
   PubMedGoogle Scholar
• World Health Organization. International Statistical Classification of Diseases and Related Health Problems. ICD-10 2010. http://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf. Accessed December 9, 2016
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015;314:142-50
   PubMed Web of Science ®Google Scholar
• Wholesale Acquisition Cost. First DataBank Inc. 2015 www.analysource.com. Accessed October 5, 2015
   Google Scholar
• Mullins CD, Rattinger GB, Kuznik A, et al. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) study. Clin Ther 2008;30:2204-16
   PubMed Web of Science ®Google Scholar
• Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004;7:397-401
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Reckless J, Davies G, Tunceli K, et al. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health 2010;13:726-34
   PubMed Web of Science ®Google Scholar
• Soini EJ, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26:25-36
   PubMed Web of Science ®Google Scholar
• van Nooten F, Davies GM, Jukema JW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J 2011;19:61-7
   PubMed Web of Science ®Google Scholar
• Monaldi B, Bologna G, Costa GG, et al. Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. Clinicoecon Outcomes Res 2015;7:273-80
   PubMed Web of Science ®Google Scholar
• O’Brien EC, McCoy LA, Thomas L, et al. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. Am Heart J 2015;170:55-61
   PubMed Web of Science ®Google Scholar
• Rannanheimo PK, Tiittanen P, Hartikainen J, et al. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health 2015;18:896-905
   PubMed Web of Science ®Google Scholar
• Johansen ME, Green LA, Sen A, et al. Cardiovascular risk and statin use in the United States. Ann Fam Med 2014;12:215-23
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Stevens J, et al. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-74, 75-118
   Web of Science ®Google Scholar